Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antivira...( SAN DIEGO April 17 /- Anadys Phar...),Health

SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) presented a late-breaker oral presentation today at the 21st International Conference on Antiviral Research (ICAR) in Montreal, Quebec, providing updated preclinical data on ANA598, a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5b polymerase.

The presentation reported several preclinical attributes of ANA598 that support the potential for beneficial combination of the product candidate with several other anti-HCV agents. Specifically, ANA598 was reported to be highly synergistic with interferon-alpha and non-antagonistic with ribavirin in cell-based assays. Furthermore, ANA598 retained full activity against a number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be used in combination with multiple other anti-HCV agents, regardless of class.

Anadys also presented the pharmacokinetic (PK) profile of ANA598 based on the results of 28-day toxicology studies. An oral dose of 20 mg/kg in monkeys provided plasma levels of ANA598 at 12 hours that were in excess of the protein-binding adjusted genotype 1a replicon EC95, suggesting the potential for twice-daily or once-daily dosing. In addition, ANA598 was tolerated in all preclinical studies up to the maximum doses tested.

"The preclinical PK profile combined with the previously reported potency of the agent provides further confidence that ANA598 will be an active antiviral in HCV infected patients," said James Freddo, M.D., Chief Medical Officer of Anadys. "The in vitro combination dat
'/>"/>